trial · primary record
Nemtabrutinib
Hematologic Malignancies
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 490 |
| Primary completion | 2029-01-04 |
| Primary endpoint | Part 1: Number of participants experiencing dose-limiting toxicities (DLTs) |
| Registry ID | NCT04728893 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:12.746Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04728893
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.